April 2024
As FDA Filing Approaches for Tab-Cel in EBV+ PTLD, Decades of Science Bear Fruit
February 23rd 2024Article
Approved in Europe, tabelecleucel may soon be considered by FDA to treat patients who develop Epstein-Barr virus following a transplant, which then triggers a type of deadly lymphoma that may not respond to traditional therapy. Tab-cel, an allogeneic T-cell therapy, comes 30 years after the discovery that T cells might offer hope, followed by decades of research on how to harness them without the side effects.
